相关实验视频

Updated: May 24, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

在患有乳腺癌的中国患者中,CYP2D6多态性和内西芬度

Cong Xue¹, Wei Yang¹, Anqi Hu¹

¹Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651# Dongfeng Road East, Guangzhou, 510060, P. R. China.

|March 6, 2025

概括

这项研究发现,CYP2D6的遗传变异会影响中国乳腺癌患者的内西芬水平. 然而,这些变化并没有显著影响他莫西芬.

科学领域:

药物基因组学药物基因组学
在瘤学瘤学.
代谢过程中的代谢.

背景情况:

塔莫西芬是乳腺癌治疗的关键药物,但它的有效性取决于它的活性代谢物,内西芬.
已知CYP2D6遗传变异会影响内分泌素水平,但亚洲人群的数据有限.
了解这些遗传影响对于个性化他莫西芬治疗至关重要.

研究的目的:

在中国的乳腺癌患者中,研究CYP2D6遗传多态性和内西芬血度之间的关联.
为了确定CYP2D6基因型是否影响他莫西芬的治疗疗效和该群体的不良影响.

主要方法:

这是一项前性研究,涉及110名中国乳腺癌患者,接受了他莫西芬治疗.
使用桑格测序识别的CYP2D6变体等位基因.
通过高性能液体染色学-并联质谱法测量的内素度.

主要成果:

最常见的是CYP2D6 *10等位基因,其中 *10/*10, *1/*10和 *2/*10基因型是常见的.
正常代谢者 (NM) 呈现出比中间代谢者 (IM) 更高的中位数内分泌素度.
尽管存在基因型相关的差异,但几乎所有患者都达到超出治疗值的内西芬水平,各组的不良事件相似.

结论:

在中国的乳腺癌患者中,CYP2D6基因型会影响内西芬的血度,IMs显示的水平低于NMs.
这些遗传变异似乎不会影响亚洲人群中他莫西芬的安全性或疗效.
这些发现支持药物遗传学测试在优化乳腺癌他莫西芬治疗中的潜在作用.

关键词:

乳腺癌乳腺癌乳腺癌在CYP2D6中.内氧化是一种内氧化.血中的度是什么塔莫西芬 (Tamoxifen) 是一种

更多相关视频

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

相关概念视频

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Factors Affecting Drug Biotransformation: Biological

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...